This padding only appears when menu bar covers the content below (browser width 1199px)

We use an alternative animal model, C. elegans, to test chemicals for neurotoxicity, developmental neurotoxicity, and developmental and reproductive toxicity. Our innovative high-throughput platform provides cost effective and rapid testing.
Protect public health with early identification of toxic chemicals
Help industries reduce animal use and meet regulatory compliance
Evaluate industrial chemicals that require further in vivo testing



Protect public health with early identification of toxic chemicals
Help industries reduce animal use and meet regulatory compliance
Evaluate industrial chemicals that require further in vivo testing
Welcome to the vivoVerse
To reflect our growing portfolio of products and services, Newormics LLC has rebranded to become vivoVerse Inc.
Latest News
vivoVerse cofounders publish single-cell isolation method using femtosecond laser microdissection (fs-LM)
vvivoVerse cofounders Dr. Adela Ben-Yakar and Dr. Sudip Mondal have published an article in Nature Methods titled “Femtosecond laser microdissection for isolation of regenerating C. elegans neurons for single-cell RNA sequencing.” This publication...
Meeting report: A successful and enjoyable time at SOT2023 in Nashville for vivoVerse
The vivoVerse team recently attended the 2023 Society of Toxicology (SOT) Annual Meeting. It was a great time networking with people in the toxicology and safety testing industry...
vivoVerse awarded SBIR Phase II grant from NIMH
vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies.
More news...